Virupaksha Organics Ltd.: Leading Manufacturer of Escitalopram Oxalate

Virupaksha Organics Ltd. continues to strengthen its position in the global pharmaceutical industry as a trusted manufacturer of Escitalopram Oxalate, an essential active pharmaceutical ingredient (API) used in the treatment of depression and anxiety disorders. Escitalopram Oxalate is the key component in widely prescribed antidepressant medications, making its consistent and high-quality production critical to improving mental health outcomes globally.

With cutting-edge manufacturing facilities in Telangana, India, Virupaksha Organics adheres to the highest standards of quality, safety, and compliance. The company’s production facilities are certified by WHO-GMP, ISO 9001, and ISO 14001, reflecting its commitment to maintaining best practices in pharmaceutical manufacturing and environmental sustainability.

Virupaksha’s focus on innovation, research, and excellence ensures that its Escitalopram Oxalate meets international regulatory standards, allowing the company to supply this crucial API to pharmaceutical companies worldwide. With a robust R&D infrastructure and advanced quality control systems, Virupaksha ensures the cost-effective and high-purity production of Escitalopram Oxalate, contributing to improved mental health treatments across the globe.

As Virupaksha Organics continues to expand its global footprint, it remains dedicated to delivering top-tier APIs like Escitalopram Oxalate that contribute to advancing healthcare and improving lives. Through its emphasis on quality, sustainability, and customer satisfaction, the company continues to be a trusted partner for pharmaceutical firms worldwide.

Other Update

Nxera Pharma Secures $10 Million Milestone Payment From AbbVie In Neurological Disease Collaboration June 30, 2026 8:45 pm RTTNews Nxera Pharma Co., Ltd. (TSE 4565) announced it will receive a US$10 million milestone payment from AbbVie, reflecting progress in their ongoing collaboration focused on developing therapies for neurological diseases. The payment marks the fourth milestone …
Palantir and the Techno-Oligarchs: Honeyed Reason, or Crushing Hegemony? June 30, 2026 8:10 pm Fair Observer The relatively recent rapid advances in AI, computing power, data mining capacity and unobtrusive surveillance technology seem to be ultimately owned and controlled by a small number of uber-wealthy corporate oligarchs. Many of these same oligarchs have …
Total number of shares and voting rights in Zealand Pharma as of June 30, 2026 June 30, 2026 8:01 pm EIN Presswire Company announcement – No. 30 / 2026 Total number of shares and voting rights in Zealand Pharma as of June 30, 2026 Copenhagen, Denmark, June 30, 2026 – Zealand Pharma A/S (“Zealand Pharma” or "the Company") (Nasdaq: ZEAL) (CVR-no. …
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. June 30, 2026 8:00 pm EIN Presswire Company announcement No. 29 / 2026 Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. Copenhagen, Denmark, June 30, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. …
How Zealand Pharma Is Scaling Quality Without Complexity June 30, 2026 7:50 pm The Medicine Maker As biotech companies grow, so does the complexity of their quality processes. How can teams expand without creating disconnected systems, duplicated work, and barriers for users? Kamilla Vagtborg, Director and Head of Quality Systems at Zealand Pharma, …
Why Early QC Planning Matters in Cell and Gene Therapy June 30, 2026 7:50 pm The Medicine Maker Manufacturing or quality deficiencies represent 74 percent of the Complete Response Letters the US FDA issued between 2020 and 2024 (1,2,3). The key factor for success or failure is not clinical efficacy as biologics final users might imagine. In cell and …
Nuvectis Pharma Stock Falls 30% June 30, 2026 7:48 pm RTTNews Shares of Nuvectis Pharma, Inc. (NVCT) are slipping about 30 percent on Tuesday morning, possibly following the company's announcement of a 5 million-share offering priced at $20.00 per share, with expected gross proceeds of $100 million. The company…
FDA rejects Unicycive and Sobi filings over contract manufacturing deficiencies June 30, 2026 6:20 pm BioSpace Manufacturing has derailed two filings for FDA approval, with the agency hitting Unicycive Therapeutics with a second rejection on production grounds and also issuing a complete response letter to Sobi. A year ago, the FDA rejected Unicycive’s request for …
IBD Drug Company Debuts with $180M June 30, 2026 6:15 pm San Diego Business Journal - California SAN DIEGO – Clinical-stage biopharmaceutical company cAMPfield Therapeutics, Inc., launched this month with the wind at its back. The company debuted with $180 million from a Series A funding round led by San Francisco Bay Area-based investment firm …
Inductive Bio joins Anthropic’s Connector Ecosystem for Life Sciences, Surfacing State-of-the-Art ADMET Prediction to Drug Discovery Scientists through Claude June 30, 2026 5:49 pm The AI Journal Inductive’s global ADMET prediction models are now available as a connector for Claude, enabling any drug discovery scientist working with Claude to access state-of-the-art predictive models directly in their existing workflow NEW YORK, June 30, 2026 / …
New Imaging Study Shows Psilocybin Alters Brain Communication Patterns, Researchers Say June 30, 2026 5:19 pm Natural News New Imaging Study Shows Psilocybin Alters Brain Communication Patterns, Researchers Say Psilocybin, the psychoactive compound in so-called magic mushrooms, temporarily alters the way the brain communicates by increasing neural signal diversity, according …
Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme June 30, 2026 5:14 pm Pharmaceutical Technology Eli Lilly and Regeneron are in the first slate of drugmakers included in a new US scheme to expedite the construction of new pharmaceutical manufacturing facilities. Lilly and Regeneron are amongst seven companies selected by the US Food and Drug …
Key U.S. complaints against Canada ahead of trade review June 30, 2026 3:57 pm BNN Bloomberg OTTAWA -- The U.S., Canada and Mexico are due to meet on July 1 to review a trilateral trade agreement after a period of heightened tensions between Washington and Ottawa. The agreement, known as CUSMA, must be reviewed every six years under a deal made …
Pictor® Holdings Inc. Secures $7.5 Million Bridge Round to Accelerate Commercialization of Targeted Proteomic Platform June 30, 2026 3:10 pm WFMZ - Pennsylvania Investment brings Pictor's total capital raised to approximately $30 million, supporting expanded U.S. and international commercialization efforts CARLSBAD, Calif., June 30, 2026 /PRNewswire/ -- Pictor Holdings Inc., a global targeted proteomic …
Cumulus Neuroscience Announces Publication in Frontiers in Digital Health Demonstrating the NeuLogiq® Platform Is Feasible and Usable for At-Home Cognitive and EEG Assessment in People Living with Mild Alzheimer's Disease Dementia June 30, 2026 2:13 pm The Kingston Whig-Standard Breadcrumb Trail Links PR Newswire Cumulus Neuroscience Logo (PRNewsfoto/Cumulus Neuroscience) Cumulus Neuroscience Article content Final results from the CNS-101 study, published in Frontiers in Digital Health, show that the NeuLogiq Platform can be …
China approved the world’s first solid tumor CAR-T therapy. When will the US follow? June 30, 2026 2:05 pm Fierce Biotech CAR-T cell therapy has flourished since its first use in 2010, leading to eight approved medicines for various blood cancers. But adapting the powerful technique, which involves engineering a patient’s own T cells to fight cancer, to solid tumors has …
Kinaset Therapeutics Appoints Daniel G. Welch as Board Chair and David Lubner as Independent Director and Audit Committee Chair June 30, 2026 1:36 pm Voice of Alexandria - Minnesota BOSTON--(BUSINESS WIRE)--Jun 30, 2026-- Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapies for serious respiratory diseases, today announced the appointments of Daniel G. Welch as Chairman of its Board of …
Morning Market Movers: AVAV, UPC, PAVS, NVCT See Big Swings June 30, 2026 1:20 pm RTTNews At 8:20 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell. For active traders, premarket trading offers a head start in spotting …
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity June 30, 2026 1:00 pm EIN Presswire NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients relied on traditional antidepressants that often took …
Amgen’s Tavneos troubles continue as NEJM retracts pivotal publication June 30, 2026 12:59 pm BioSpace The New England Journal of Medicine has retracted a paper that presented pivotal data for Amgen’s Tavneos, adding to the pharma’s woes over its rare disease drug. Two of the study’s authors requested the retraction, according to an NEJM note published June …
Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial June 30, 2026 12:30 pm EIN Presswire Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104 Greater improvements observed in children with preexisting genu varum (leg bowing) COPENHAGEN, …
Packaging News Sustainability PowerBook | Keep Britain Tidy, Solstice Advanced Materials June 30, 2026 12:25 pm Packaging News The Packaging News Sustainability PowerBook brings together the 50 people driving real change across brands, retailers, manufacturers, policy and innovation. Every name is chosen by the PN editorial team, with advisory consultants, on merit. The full list …
HLTH Europe 2026: Healthcare implementation key amid European innovation rush June 30, 2026 11:47 am Pharmaceutical Technology As healthcare players from Europe and further afield continue to produce potentially game-changing healthcare innovations, attendees at HLTH Europe 2026 turned their attention to how these technologies, pharmaceutical products and medical devices can best …
Transformative Trends Driving the Pharmaceutical Industry Forward June 30, 2026 11:43 am Pharma Tech Outlook By Pharma Tech Outlook | Monday, June 29, 2026 Fremont, CA: Navigating a complex and highly regulated environment, the pharmaceutical industry must keep pace with evolving regulatory trends to maintain compliance and competitiveness. Technological …
Driving Confidence in Pharmaceuticals Through ESG Practices June 30, 2026 11:43 am Pharma Tech Outlook Fremont, CA: Sustainability and ESG principles are increasingly vital in the pharmaceutical industry, as stakeholders expect greater accountability for product safety, efficacy, and their environmental and societal impact. As global health challenges …

Pharma News Hyderabad

Pharma News Hyderabad

Virupaksha Organics Ltd.: Leading Manufacturer of Escitalopram Oxalate

Other Update